Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 28.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,745 shares of the biopharmaceutical company's stock after selling 13,146 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Regeneron Pharmaceuticals were worth $21,403,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in REGN. Rakuten Securities Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. TD Private Client Wealth LLC boosted its position in Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after acquiring an additional 15 shares during the last quarter. Adirondack Trust Co. grew its stake in Regeneron Pharmaceuticals by 4.2% in the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after acquiring an additional 18 shares during the period. Prestige Wealth Management Group LLC grew its stake in Regeneron Pharmaceuticals by 23.2% in the 4th quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock worth $72,000 after acquiring an additional 19 shares during the period. Finally, Ashton Thomas Securities LLC raised its holdings in Regeneron Pharmaceuticals by 2.5% in the 4th quarter. Ashton Thomas Securities LLC now owns 810 shares of the biopharmaceutical company's stock valued at $577,000 after acquiring an additional 20 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $3.86 during trading hours on Friday, reaching $509.72. The company's stock had a trading volume of 2,259,294 shares, compared to its average volume of 889,828. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The business has a 50-day simple moving average of $558.34 and a 200 day simple moving average of $640.90. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The stock has a market cap of $55.03 billion, a PE ratio of 12.98, a PEG ratio of 1.87 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $9.55 EPS. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.69%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on REGN. Robert W. Baird reduced their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. The Goldman Sachs Group dropped their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Citigroup lowered their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 2nd. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. Finally, JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.